# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0176 |
| PP ID | PP-0176 |
| Title | Endoscopic Diagnosis of Gastric Cancer |
| Version | 1.0.0 |
| Status | PASS — GOLD |

# Layer 1 — Content QA

| Criterion | Result |
|---|---|
| Atomic clinical question | PASS |
| Approved PP identity | PASS |
| Full-depth CKO structure | PASS |
| Full-depth Knowledge Passport | PASS |
| Full-depth Evidence Package | PASS |
| Granular knowledge blocks | PASS |
| Patient Explanation per block | PASS |
| Clinical Importance per block | PASS |
| Key Concepts per block | PASS |
| Common Misconceptions | PASS |
| Key Messages | PASS |
| Knowledge Graph | PASS |
| Revision History | PASS |
| Included scope | PASS |
| Not Included scope | PASS |

# Layer 2 — Clinical QA

| Criterion | Result |
|---|---|
| Source-first clinical grounding | PASS |
| NCCN v2.2026 GAST-A represented | PASS |
| NCI HDGC evidence represented | PASS |
| NCI gastric-cancer genetics evidence represented | PASS |
| Vietnam diagnostic guideline represented | PASS |
| Diagnostic endoscopy correctly defined | PASS |
| Screening vs diagnostic distinction | PASS |
| Diagnostic vs surveillance distinction | PASS |
| Lesion morphology appropriately bounded | PASS |
| Location / EGJ documentation | PASS |
| Systematic examination concept | PASS |
| Endoscopy vs pathology distinction | PASS |
| Biopsy transition correctly bounded | PASS |
| Diffuse/infiltrative disease limitation | PASS |
| Microscopic disease limitation | PASS |
| Endoscopy-pathology discordance | PASS |
| EUS interface correctly bounded | PASS |
| EMR/ESD interface correctly bounded | PASS |
| No unsupported universal protocol | PASS |
| No individualized diagnosis | PASS |
| No treatment recommendation | PASS |

# Layer 3 — Educational QA

| Criterion | Result |
|---|---|
| Patient-centered framing | PASS |
| Plain-language explanation | PASS |
| Medical terminology explained | PASS |
| One-concept-per-block architecture | PASS |
| Diagnostic pathway logically sequenced | PASS |
| Screening/diagnosis/surveillance distinction clear | PASS |
| Suspicion vs confirmation distinction clear | PASS |
| Diagnostic limitations explicit | PASS |
| Common misconceptions addressed | PASS |
| Appropriate uncertainty | PASS |
| No alarmist wording | PASS |
| No individualized clinical instruction | PASS |

# Layer 4 — Governance QA

| Criterion | Result |
|---|---|
| CORE_WORKING_RULES v1.6 | PASS |
| WR-011 Source-First | PASS |
| WR-012 User-Controlled Sequence | PASS |
| WR-013 Single Decision Batch | PASS |
| WR-014 Gold Discussion Template Adherence | PASS |
| WR-014A Adjacent PP Overlap Check | PASS |
| WR-010 Immediate Gold Production | PASS |
| Gold Specification v1.0 | PASS |
| Four artifacts complete | PASS |
| Full-depth / non-compacted production | PASS |
| Boundary structure compliant | PASS |
| Knowledge Graph included | PASS |
| Evidence traceability included | PASS |
| Semantic versioning | PASS |
| Repository-ready structure | PASS |

# Full-Depth Compliance Check

This package was produced under the project's absolute full-depth rule.

The CKO contains **30 granular Clinical Knowledge Blocks**, each independently structured as:

1. Patient Explanation;
2. Clinical Importance;
3. Key Concepts.

The CKO additionally contains:

- Metadata;
- Educational Objectives;
- Scope;
- Included;
- Not Included;
- Common Misconceptions;
- Key Messages;
- Knowledge Graph;
- Prerequisite PPs;
- Related PPs;
- Next / Downstream PPs;
- Revision History.

The Knowledge Passport independently covers:

- Identity;
- Knowledge Classification;
- Patient Journey Classification;
- Intended Runtime Usage;
- Retrieval / Runtime Relevance;
- Clinical Scope;
- Authoritative Sources;
- Evidence Classification;
- Governance Metadata;
- Version Control;
- Change History;
- Final Status.

The Primary Evidence Package independently covers:

- Identity;
- Clinical Question;
- Educational Intent;
- Scope;
- Primary Evidence Sources;
- Supporting Sources;
- Evidence Hierarchy;
- Evidence Matrix;
- Evidence Notes;
- Clinical Claims Summary;
- Evidence Consistency Review;
- Evidence Gaps;
- Out-of-Scope Topics;
- Future Update Triggers;
- Source Traceability;
- Boundary Verification;
- Evidence Package Decision;
- Final Evidence Status.

The QA Report independently evaluates all four QA layers and includes a dedicated full-depth compliance audit.

**The package is explicitly non-compacted and is at least as deep as the approved Gold reference standard.**

# Boundary QA

**Boundary: Core = gastric-cancer-specific diagnostic endoscopy, including direct visualization and recognition of suspicious gastric neoplasia, lesion morphology at a conceptual level, focal versus diffuse/infiltrative patterns, lesion location, size, extent, relationship to the esophagogastric junction, systematic examination and documentation, distinction between endoscopic suspicion and confirmed diagnosis, limitations of visual detection, and the transition from suspicious findings to tissue sampling; Supporting = selected discussion of subtle/early lesions, microscopic or diffuse disease, endoscopy–pathology discordance, selected EUS and EMR/ESD diagnostic-staging interfaces, and the role of endoscopic findings in downstream planning; Explicitly Excluded = general endoscopy preparation, sedation/anesthesia, post-procedure care, procedural complications, detailed biopsy number/site/technique, histopathologic classification, Lauren classification, molecular/biomarker testing, detailed EUS or imaging methodology, full TNM staging, EMR/ESD technique, therapeutic endoscopy, hereditary gastric-cancer surveillance protocols, and individualized diagnosis or treatment; Delegated-to PP = PP-0175 Gastric Cancer Diagnostic Work-up, PP-0177 Endoscopic Biopsy Strategy, PP-0178 Histopathologic Classification, PP-0179 Lauren Classification, PP-0180 Gastric Cancer Molecular Classification, PP-0181+ Biomarker Testing, PP-0159 Hereditary Diffuse Gastric Cancer Surveillance, dedicated EUS/imaging/staging packages, and PP-0192–0194 Endoscopic Resection/EMR/ESD.**

# Architecture QA

PP-0176 remains the specialized endoscopic diagnostic layer between the integrated diagnostic work-up and the tissue/pathology packages.

It does not absorb:

- overall diagnostic work-up;
- biopsy strategy;
- histopathology;
- Lauren classification;
- molecular classification;
- biomarker testing;
- detailed EUS/imaging;
- endoscopic resection;
- treatment.

The principal ownership chain remains:

**PP-0175 — overall diagnostic work-up**

→ **PP-0176 — endoscopic visualization/localization/characterization**

→ **PP-0177 — tissue acquisition**

→ **PP-0178 — pathology**

→ **PP-0179 — Lauren**

→ **PP-0180 — molecular classification**

→ **PP-0181+ — biomarkers**

# Final QA Decision

## PASS

All four Gold artifacts are complete, full-depth, source-grounded, clinically bounded, and aligned with the approved/locked PP-0176 Decision Batch.

# QA Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
